Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.73 |
| ▸ | SIK2 | Q9H0K1 | 12/20 | 0.73 |
| ▸ | SIK3 | Q9Y2K2 | 12/20 | 0.73 |
| ▸ | SIK1 | P57059 | 10/20 | 0.73 |
| ▸ | SRC | P12931 | 6/20 | 0.71 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.69 |
| ▸ | KIT | P10721 | 4/20 | 0.67 |
| ▸ | BCR | P11274 | 3/20 | 0.67 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.67 |
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | CSF1R | P07333 | 2/20 | 0.67 |
| ▸ | YES1 | P07947 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.67 |
| ▸ | HCK | P08631 | 2/20 | 0.67 |
| ▸ | BRAF | P15056 | 2/20 | 0.67 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29885048 | 1.00 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| Water SCHEMBL3226546 | 0.99 | ABL1 (0.72) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL3536666 | 0.91 | ABL1 (0.75) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL30144989 | 0.91 | ABL1 (0.75) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL14141736 | 0.90 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL12438117 | 0.90 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL18971581 | 0.90 | ABL1 (0.72) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL31688158 | 0.89 | SIK2 (0.66) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL14141969 | 0.88 | ABL1 (0.70) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL14142047 | 0.86 | SIK2 (0.68) | ABL1SIK2SIK3SIK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021074620-A1 | [1,4]OXAZEPINO[2,3-C]QUI NOLI NONE DERIVATIVES AS BLC6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021032129-A1 | KINASE INHIBITOR, PREPARATION THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 湖南华纳大药厂股份有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-20180055887-A1 | METHOD FOR PREPARING INDUCED MESENCHYMAL STEM CELLS AND IMPROVING MESENCHYMAL STEM CELL'S CHARACTERS AND ITS APPLICATIONS | ACADEMIA SINICA (TW) | 2018-03-01 | — | — | US | disclosed |
| CN-104292223-A | Novel synthetic method of dasatinib | CHANGZHOU RUIBO BIO TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | disclosed |
| CN-101948467-B | Thiazoleamide compound and use thereof for the preparation of anti-malignant tumor medicines | SUZHOU BORUI PHARMACEUTICAL INC | 2012-07-25 | — | — | CN | disclosed |
| CN-101973989-B | Thiazole amide compound and medicinal application thereof for treating malignancy | SUZHOU BORUI PARMACEUTICALS INC | 2012-07-18 | — | — | CN | disclosed |
| CN-101967142-B | Thiazoleamide compound and medical application thereof in treating malignant tumor | SUZHOU BORUI BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2012-05-30 | — | — | CN | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055887-A1 | METHOD FOR PREPARING INDUCED MESENCHYMAL STEM CELLS AND IMPROVING MESENCHYMAL STEM CELL'S CHARACTERS AND ITS APPLICATIONS | NES, MYADM, CXCL12 | ABL1 3959/4885SIK2 1791/4885SIK3 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.